Loading clinical trials...
Loading clinical trials...
A Two-stage Clinical Trial With Dose Escalation at the First Stage and a Single-blind, Placebo-controlled Clinical Trial for Evaluation of Efficacy, Safety, Reactogenicity and Immunogenicity of GNR-127 at the Second Stage in Patients With Allergic Rhinitis Sensitized to Birch Pollen.
Conditions
Interventions
GNR-127, 20 mcg
GNR-127, 40 mcg
+2 more
Locations
1
Russia
National Research Center - Institute of Immunology Federal Medical-Biological Agency
Moscow, Russia
Start Date
October 7, 2024
Primary Completion Date
May 31, 2025
Completion Date
December 20, 2025
Last Updated
September 4, 2025
NCT00127647
NCT00092885
NCT00406783
NCT00135629
NCT04622917
NCT02975479
Lead Sponsor
AO GENERIUM
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions